...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Urology >A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
【24h】

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients

机译：促性腺激素释放激素拮抗剂可降低前列腺癌患者的血清肾上腺雄激素水平

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Adrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen levels in patients treated with a GnRH antagonist. Methods This study included 47 patients with histologically proven prostate cancer. All of the patients were treated with the GnRH antagonist degarelix. The mean patient age was 73.6?years. Pre-treatment blood samples were collected from all of the patients, and post-treatment samples were taken at 1, 3, 6, and 12?months after starting treatment. Testosterone (T), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), 17β-estradiol (E2), and androstenedione (A-dione) were measured by liquid chromatography-mass spectrometry. Dehydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone, and follicle-stimulating hormone levels were measured by electro-chemiluminescence immunoassays. Results A significant reduction in T level (97.3% reduction) was observed in the patients 1?month after initiating treatment. In addition, levels of DHT, E2, DHEA-S, and A-dione decreased 1?month after initiating treatment (93.3, 84.9, 16.8, and 35.9% reduction, respectively). T, DHT, E2, DHEA-S, and A-dione levels remained significantly suppressed (97.1, 94.6, 85.3, 23.9, and 40.5% reduction, respectively) 12?months after initiating treatment. A significant decrease in DHEA level (15.4% reduction) was observed 12?months after initiating treatment. Conclusions Serum adrenal androgen levels decreased significantly in patients treated with a GnRH antagonist. Thus, long-term GnRH antagonist treatment may reduce serum adrenal androgen levels.
机译：背景技术肾上腺雄激素在去势抵抗性前列腺癌疗法的发展中起着重要作用。促性腺激素释放激素（GnRH）拮抗剂对肾上腺雄激素的作用尚未得到充分研究。我们测量了接受GnRH拮抗剂治疗的患者的睾丸和肾上腺雄激素水平。方法该研究纳入了47例经组织学证实为前列腺癌的患者。所有患者均接受GnRH拮抗剂地加瑞克治疗。患者平均年龄为73.6岁。从所有患者中收集治疗前的血样，并在开始治疗后的1、3、6和12个月时采集治疗后的血样。通过液相色谱-质谱法测定睾丸激素（T），二氢睾丸激素（DHT），脱氢表雄酮（DHEA），17β-雌二醇（E2）和雄烯二酮（A-二酮）。硫酸脱氢表雄酮（DHEA-S），促黄体生成激素和促卵泡激素水平通过电化学发光免疫分析法进行测定。结果开始治疗后1个月，患者的T水平显着降低（降低了97.3％）。此外，开始治疗后1个月，DHT，E2，DHEA-S和A-二酮的水平下降了（分别下降了93.3％，84.9％，16.8％和35.9％）。在开始治疗后12个月，T，DHT，E2，DHEA-S和A-二酮的水平仍然受到显着抑制（分别降低97.1％，94.6％，85.3％，23.9％和40.5％）。开始治疗后12个月，DHEA水平显着下降（下降了15.4％）。结论GnRH拮抗剂治疗的患者血清肾上腺雄激素水平显着降低。因此，长期的GnRH拮抗剂治疗可能会降低血清肾上腺雄激素水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号